Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received approval for “URECE® Tablets” (dotinurad) in Thailand as a treatment for gout and hyperuricemia. This approval is the first time that the agent has been approved in China or the five ASEAN (Association of Southeast Asian Nations) member states where Eisai holds licenses to develop and distribute the agent. “URECE Tablets” are a new therapeutic medicine for gout and hyperuricemia discovered by FUJI YAKUHIN.

卫材株式会社（总部：东京，CEO：Haruo Naito，“卫材”）今天宣布，它已获得泰国“URECE®片剂”（dotinurad）的批准，用于治疗痛风和高尿酸血症。这是该代理首次在中国或卫材持有开发和分销代理许可证的东盟（东盟）五个成员国获得批准。“尿毒症片”是富士雅库欣发现的治疗痛风和高尿酸血症的新药物。

It suppresses uric acid reabsorption and lowers blood uric acid levels by selectively inhibiting the urate transporter (URAT1) related to reabsorption of uric acid in the kidney. Eisai concluded a license agreement with FUJI YAKUHIN in February 2020 for China and in August 2021 for five ASEAN member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand, granting exclusive development and distribution rights in these countries. Hyperuricemia is known to be associated with various diseases, including those of the urinary system, endocrine system, metabolic system, and cardio-cerebrovascular system, as well as gout.

它通过选择性抑制与肾脏尿酸重吸收相关的尿酸盐转运蛋白（URAT1）来抑制尿酸重吸收并降低血尿酸水平。卫材于2020年2月与富士雅库欣（FujiYakuhin）签订了中国许可协议，并于2021年8月与五个东盟成员国（印度尼西亚、马来西亚、缅甸、菲律宾和泰国）签订了许可协议，授予这些国家的独家开发和分销权。已知高尿酸血症与各种疾病有关，包括泌尿系统，内分泌系统，代谢系统和心脑血管系统以及痛风。

Furthermore, the prevalence of hyperuricemia in Thailand is estimated to be as high as 10.6%.1 It is expected that the number of patients will further increase in the near future due to changes in lifestyle and dietary preferences in accordance with socioeconomic development. Eisai is committed to providing new treatment options for gout and hyperuricemia in China and the applicable ASEAN member states, and will further contribute to improving the quality of life (QOL) of patients.  Media Inquiries:Eisai Co., Ltd.Public Relations DepartmentTEL: +81-(0)3-3817-5120  <Notes to editors>About “URECE® Tablets” (Dotinurad)URECE Tablets are a therapeuti.

此外，泰国高尿酸血症的患病率估计高达10.6%[1]。根据社会经济发展，由于生活方式和饮食偏好的改变，预计患者人数将在不久的将来进一步增加。卫材致力于为中国和适用的东盟成员国的痛风和高尿酸血症提供新的治疗选择，并将进一步提高患者的生活质量。。